|
AU3210997A
(en)
*
|
1996-05-24 |
1997-12-09 |
University Of Maryland At Baltimore |
Dna vaccines for eliciting a mucosal immune response
|
|
US5980898A
(en)
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
|
ES2279580T3
(es)
*
|
1997-09-15 |
2007-08-16 |
Genetic Immunity, Llc |
Composiciones para administrar genes a celulas de la piel que presentan antigenos.
|
|
CA2314683A1
(en)
*
|
1997-12-12 |
1999-06-24 |
Luigi Naldini |
Therapeutic use of lentiviral vectors
|
|
WO1999047146A1
(en)
*
|
1998-03-17 |
1999-09-23 |
Julianna Lisziwiewicz |
Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
|
|
US6461616B1
(en)
*
|
2000-09-09 |
2002-10-08 |
Akzo Nobel Nv |
EIAV p26 deletion vaccine and diagnostic
|
|
US20070025958A1
(en)
|
2000-10-27 |
2007-02-01 |
Hadden John W |
Vaccine immunotherapy
|
|
CA2950109C
(en)
|
2000-10-27 |
2019-02-19 |
John W. Hadden |
Vaccine immunotherapy for immune suppressed patients
|
|
US7628980B2
(en)
|
2000-11-23 |
2009-12-08 |
Bavarian Nordic A/S |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
US7097842B2
(en)
|
2000-11-23 |
2006-08-29 |
Bavarian Nordic A/S |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
US7445924B2
(en)
|
2000-11-23 |
2008-11-04 |
Bavarian Nordic A/S |
Modified Vaccinia Ankara virus variant and cultivation method
|
|
DE20122302U1
(de)
|
2000-11-23 |
2005-02-24 |
Bavarian Nordic A/S |
Variante des Modifizierten Vaccinia-Ankara-Virus
|
|
PT1372708E
(pt)
|
2001-02-13 |
2008-09-29 |
Us Gov Sec Army |
Vacina para imunização transcutânea
|
|
AU2002356690B2
(en)
|
2001-12-04 |
2008-07-24 |
Bavarian Nordic A/S |
Flavivirus NS1 subunit vaccine
|
|
JP4801880B2
(ja)
|
2002-04-19 |
2011-10-26 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
新生仔予防接種用変異ワクシニアウイルスアンカラ
|
|
UA85543C2
(ru)
|
2002-09-05 |
2009-02-10 |
Бавариан Нордик А/С |
Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
|
|
WO2004065575A2
(en)
*
|
2003-01-15 |
2004-08-05 |
Research Institute For Genetic And Human Therapy (Right) |
Dna compositon and uses thereof
|
|
FR2872170B1
(fr)
*
|
2004-06-25 |
2006-11-10 |
Centre Nat Rech Scient Cnrse |
Lentivirus non interactif et non replicatif, preparation et utilisations
|
|
EP1797189A4
(en)
*
|
2004-09-02 |
2010-05-19 |
Qun Chen |
ENCAPSIDATION SYSTEM FOR THE PRODUCTION OF RECOMBINANT VIRUSELY PARTICLES
|
|
GB0526211D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Viral vectors
|
|
ES2654303T3
(es)
|
2007-05-04 |
2018-02-13 |
University Health Network |
Inmunoterapia de IL-12 contra el cáncer
|
|
AU2008329741B2
(en)
|
2007-11-28 |
2013-09-12 |
Irx Therapeutics, Inc. |
Method of increasing immunological effect
|
|
WO2010009465A2
(en)
*
|
2008-07-18 |
2010-01-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Htlv-ii vector and methods of use
|
|
CA3017298C
(en)
|
2009-05-15 |
2021-09-28 |
Irx Therapeutics, Inc. |
Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
|
|
CN103097543A
(zh)
|
2009-12-08 |
2013-05-08 |
伊尔克斯治疗有限公司 |
逆转朗格汉斯细胞免疫抑制的方法
|